Neoadjuvant ceritinib treatment achieved pathological complete response in patients with anaplastic lymphoma kinase positive stage IIIA-N2 non-small cell lung cancer.
10.1097/CM9.0000000000002403
- Author:
Qian SHEN
1
;
Qiqi GAO
2
;
Jianying ZHOU
1
Author Information
1. Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China.
2. Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China.
- Publication Type:Letter
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/therapy*;
Lung Neoplasms/pathology*;
Anaplastic Lymphoma Kinase;
Neoadjuvant Therapy;
Protein Kinase Inhibitors
- From:
Chinese Medical Journal
2023;136(7):851-853
- CountryChina
- Language:English
